Efficacy and Safety of Tumour-Treating Fields Combined with Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma Patients

Abstract Introduction: Tumour-treating fields (TTFields) have demonstrated efficacy in extending survival in the temozolomide maintenance therapy phase. We present a retrospective analysis of newly diagnosed Chinese glioblastoma patients treated at Jiangsu Cancer Hospital from September 2021 to December 2023 to evaluate the efficacy and safety of TTFields combined with concurrent chemoradiotherapy for these patients. Methods: Progression-free survival (PFS) curves were constructed using the Kaplan–Meier method. A Cox proportional hazards regression model was used to assess the effect of TTFields and to account for confounding factors. Results: Among the 58 glioblastoma patients included in the study, the median progression-free survival (PFS) was 11.7 months (95% CI: 9.4-14.0), with a 6-month PFS rate of 88.5%. The objective response rate (ORR) was 58.6% (34/58), and the disease control rate (DCR) was 93.1% (54/58). Mild to moderate skin toxicity underneath the transducer arrays occurred in 56.9% of patients. Multivariate analysis revealed that surgery type and compliance rate with TTFs were favourable prognostic factors. Conclusion: In our final analysis of single-centre Chinese patients with newly diagnosed glioblastoma, concurrent chemoradiotherapy with TTFields resulted in a statistically significant improvement in PFS and demonstrated improved safety profiles.